DOP2012000006A - Agonista de gpr119 - Google Patents
Agonista de gpr119Info
- Publication number
- DOP2012000006A DOP2012000006A DO2012000006A DO2012000006A DOP2012000006A DO P2012000006 A DOP2012000006 A DO P2012000006A DO 2012000006 A DO2012000006 A DO 2012000006A DO 2012000006 A DO2012000006 A DO 2012000006A DO P2012000006 A DOP2012000006 A DO P2012000006A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- gpr119 agonist
- gpr119
- agonist
- obesity
- diabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Abstract
Los compuestos agonistas de GPR119 de la fórmula: y composiciones farmacéuticas para el tratamiento de diabetes y obesidad.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09382114 | 2009-07-15 | ||
US24544509P | 2009-09-24 | 2009-09-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2012000006A true DOP2012000006A (es) | 2012-01-31 |
Family
ID=43449712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2012000006A DOP2012000006A (es) | 2009-07-15 | 2012-01-11 | Agonista de gpr119 |
Country Status (24)
Country | Link |
---|---|
US (1) | US8207344B2 (es) |
EP (1) | EP2454251A1 (es) |
JP (1) | JP5715127B2 (es) |
KR (1) | KR101365854B1 (es) |
CN (1) | CN102471313B (es) |
AR (1) | AR077638A1 (es) |
AU (1) | AU2010273642B2 (es) |
BR (1) | BRPI1015921A2 (es) |
CA (1) | CA2764906C (es) |
CO (1) | CO6480977A2 (es) |
CR (1) | CR20120012A (es) |
DO (1) | DOP2012000006A (es) |
EA (1) | EA020540B1 (es) |
EC (1) | ECSP12011606A (es) |
IL (1) | IL216776A0 (es) |
MA (1) | MA33428B1 (es) |
MX (1) | MX2012000704A (es) |
NZ (1) | NZ597125A (es) |
PE (1) | PE20121045A1 (es) |
SG (1) | SG177646A1 (es) |
TN (1) | TN2012000002A1 (es) |
TW (1) | TWI429634B (es) |
WO (1) | WO2011008663A1 (es) |
ZA (1) | ZA201200227B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004065380A1 (en) | 2003-01-14 | 2004-08-05 | Arena Pharmaceuticals Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
JP2013522279A (ja) | 2010-03-18 | 2013-06-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連状態の治療で用いるgpr119作動薬とddp−iv阻害薬リナグリプチンの組合せ |
PE20131371A1 (es) | 2010-09-22 | 2013-11-25 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este |
WO2012135570A1 (en) * | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP2693882B1 (en) | 2011-04-08 | 2017-06-28 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
WO2012170702A1 (en) * | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
ES2602813T3 (es) | 2011-06-09 | 2017-02-22 | Rhizen Pharmaceuticals S.A. | Nuevos compuestos como moduladores de GPR-119 |
EP2720544B1 (en) | 2011-06-16 | 2016-12-21 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment |
WO2013048916A1 (en) * | 2011-09-30 | 2013-04-04 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
WO2013062835A1 (en) * | 2011-10-24 | 2013-05-02 | Merck Sharp & Dohme Corp. | Substituted piperidinyl compounds useful as gpr119 agonists |
WO2013062838A1 (en) | 2011-10-24 | 2013-05-02 | Merck Sharp & Dohme Corp. | Substituted piperidinyl compounds useful as gpr119 agonists |
US9018224B2 (en) | 2011-11-15 | 2015-04-28 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as GPR119 agonists |
ES2759010T3 (es) * | 2012-06-12 | 2020-05-07 | Chong Kun Dang Pharmaceutical Corp | Derivados de piperidina como agonistas del GPR119 |
EP2872127A1 (en) | 2012-07-11 | 2015-05-20 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
WO2014052619A1 (en) * | 2012-09-27 | 2014-04-03 | Irm Llc | Piperidine derivatives and compositions as modulators of gpr119 activity |
JP6182269B2 (ja) | 2013-11-26 | 2017-08-16 | チョン クン ダン ファーマシューティカル コーポレーション | Gpr119アゴニストとしてのアミド誘導体 |
KR101651505B1 (ko) * | 2014-05-02 | 2016-08-29 | 현대약품 주식회사 | 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
KR20230151072A (ko) | 2015-01-06 | 2023-10-31 | 아레나 파마슈티칼스, 인크. | S1p1 수용체와 관련된 상태의 치료 방법 |
CA3002551A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders |
MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
AU2021275038A1 (en) | 2020-05-19 | 2022-12-22 | Kallyope, Inc. | AMPK activators |
CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004065380A1 (en) * | 2003-01-14 | 2004-08-05 | Arena Pharmaceuticals Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
JP2010501629A (ja) * | 2006-08-30 | 2010-01-21 | ビオヴィトルム・アクチボラゲット(プブリクト) | Gpr119関連障害を治療するためのピリジン化合物 |
US7638541B2 (en) * | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
NZ583495A (en) * | 2007-09-20 | 2011-11-25 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
-
2010
- 2010-07-06 AR ARP100102424A patent/AR077638A1/es not_active Application Discontinuation
- 2010-07-08 TW TW099122534A patent/TWI429634B/zh not_active IP Right Cessation
- 2010-07-12 WO PCT/US2010/041645 patent/WO2011008663A1/en active Application Filing
- 2010-07-12 EP EP10734412A patent/EP2454251A1/en not_active Withdrawn
- 2010-07-12 SG SG2012002523A patent/SG177646A1/en unknown
- 2010-07-12 CA CA2764906A patent/CA2764906C/en not_active Expired - Fee Related
- 2010-07-12 MX MX2012000704A patent/MX2012000704A/es active IP Right Grant
- 2010-07-12 JP JP2012520691A patent/JP5715127B2/ja not_active Expired - Fee Related
- 2010-07-12 PE PE2012000041A patent/PE20121045A1/es not_active Application Discontinuation
- 2010-07-12 KR KR1020127000996A patent/KR101365854B1/ko not_active IP Right Cessation
- 2010-07-12 CN CN201080031375.4A patent/CN102471313B/zh not_active Expired - Fee Related
- 2010-07-12 AU AU2010273642A patent/AU2010273642B2/en not_active Ceased
- 2010-07-12 MA MA34531A patent/MA33428B1/fr unknown
- 2010-07-12 BR BRPI1015921A patent/BRPI1015921A2/pt not_active IP Right Cessation
- 2010-07-12 EA EA201270169A patent/EA020540B1/ru not_active IP Right Cessation
- 2010-07-12 US US12/834,054 patent/US8207344B2/en not_active Expired - Fee Related
- 2010-07-12 NZ NZ597125A patent/NZ597125A/xx not_active IP Right Cessation
-
2011
- 2011-12-05 IL IL216776A patent/IL216776A0/en unknown
- 2011-12-29 CO CO11181048A patent/CO6480977A2/es active IP Right Grant
-
2012
- 2012-01-02 TN TNP2012000002A patent/TN2012000002A1/en unknown
- 2012-01-09 CR CR20120012A patent/CR20120012A/es unknown
- 2012-01-11 DO DO2012000006A patent/DOP2012000006A/es unknown
- 2012-01-11 ZA ZA2012/00227A patent/ZA201200227B/en unknown
- 2012-01-13 EC EC2012011606A patent/ECSP12011606A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2010273642B2 (en) | 2014-03-13 |
CA2764906C (en) | 2014-06-10 |
ECSP12011606A (es) | 2012-02-29 |
PE20121045A1 (es) | 2012-08-09 |
KR101365854B1 (ko) | 2014-02-21 |
EA020540B1 (ru) | 2014-11-28 |
US20110015199A1 (en) | 2011-01-20 |
JP2012533546A (ja) | 2012-12-27 |
BRPI1015921A2 (pt) | 2016-04-26 |
CN102471313A (zh) | 2012-05-23 |
ZA201200227B (en) | 2013-06-26 |
AU2010273642A1 (en) | 2012-01-19 |
CR20120012A (es) | 2012-03-28 |
KR20120024964A (ko) | 2012-03-14 |
TN2012000002A1 (en) | 2013-09-19 |
JP5715127B2 (ja) | 2015-05-07 |
IL216776A0 (en) | 2012-03-01 |
CA2764906A1 (en) | 2011-01-20 |
MA33428B1 (fr) | 2012-07-03 |
EA201270169A1 (ru) | 2012-06-29 |
NZ597125A (en) | 2013-08-30 |
EP2454251A1 (en) | 2012-05-23 |
AR077638A1 (es) | 2011-09-14 |
TWI429634B (zh) | 2014-03-11 |
TW201114757A (en) | 2011-05-01 |
CN102471313B (zh) | 2014-06-04 |
MX2012000704A (es) | 2012-03-07 |
US8207344B2 (en) | 2012-06-26 |
CO6480977A2 (es) | 2012-07-16 |
WO2011008663A1 (en) | 2011-01-20 |
SG177646A1 (en) | 2012-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2012000006A (es) | Agonista de gpr119 | |
CL2009000426A1 (es) | Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas | |
EA201170151A1 (ru) | Пиперидиниловые агонисты gpcr | |
CL2012000937A1 (es) | Compuestos heterociclicos espiro derivados de ciclohexano, inhibidores de hsl; procedimiento de preparacion; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento de diabetes, sindrome metabolico, dislipidemia, aterosclerosis u obesidad. | |
EA201100037A1 (ru) | Органические соединения | |
CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
ATE557024T1 (de) | Piperidinverbindungen als gpcr-agonisten | |
MX2009007180A (es) | Agonistas del receptor acoplado a la proteina g de la piperidina. | |
CL2012001722A1 (es) | Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes. | |
CL2008001049A1 (es) | Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad. | |
ATE557023T1 (de) | Piperidinylverbindungen als gpcr-agonisten | |
CL2012003681A1 (es) | Compuestos derivados de piperidina; composicion farmaceutica; y su uso como inhibidores de acetil-coa carboxilasa para el tratamiento de trastornos metabolicos, tales como obesidad y diabetes. | |
CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
SV2011003809A (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
CL2007002890A1 (es) | Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad. | |
CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
EA201101116A1 (ru) | Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина | |
CL2008000110A1 (es) | Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos. | |
EA201101118A1 (ru) | Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина | |
CL2010000804A1 (es) | Compuestos derivados de 3-(1 h-pirrol-2-il-metil)-1 ,3-dihidro-2h-indol-2-ona; procedimientos de preparación de dichos compuestos; composición farmacéutica y combinación farmacéutica que los comprende; y su uso para el tratamiento de cáncer. | |
CL2011000168A1 (es) | Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer. | |
CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
UY33305A (es) | Compuestos heterocíclicos inhibidores de DGAT1 | |
ES1065640Y (es) | Aparato para el alargamiento del pene | |
BRPI0912890A2 (pt) | composição farmacêutica para o tratamento de ejaculação precoce |